Research Advances on Mechanisms of Resistance to All-Trans Retinoic Acid in Acute Promyelocytic Leukemia--Review.
10.7534/j.issn.1009-2137.2019.06.052
- Author:
Ya-Na NIU
1
;
Wen-Jun LIU
2
Author Information
1. Department of Pediatric Hematology and Oncology, PI Research Laboratory of Children's Hematology and Oncology, Affiliated Hospital of Southwest Medical University, Luzhou 646000, Sichuan Province, China.
2. Department of Pediatric Hematology and Oncology, PI Research Laboratory of Children's Hematology and Oncology, Affiliated Hospital of Southwest Medical University, Luzhou 646000, Sichuan Province, China,E-mail: lwjlyfy@qq.com.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Agents;
Cell Differentiation;
Humans;
Leukemia, Promyelocytic, Acute;
Tretinoin
- From:
Journal of Experimental Hematology
2019;27(6):2024-2029
- CountryChina
- Language:Chinese
-
Abstract:
Abstract Among myeloid leukemias, the acute promyelocytic leukemia (APL) was found to be specifically sensitive to all-trans retinoic acid (ATRA), almost all APL patients respond to ATRA therapy. The ATRA induces remission of APL patients by stimulating the differentiation of the leukemia cells. However, with the long-term application of ATRA alone, ATRA resistance has become one of the main causes of chemotherapy failure in the patients with acute promyelocytic leukemia. At present, the mechanism of ATRA-resistance is not completely clear, this review discusses the mechanism of drug-resistance in terms of signal pathways, genes, proteins and enzyme.
